Amicus Therapeutics Case Study
News of the latest advancements in strategies and treatment against many rare diseases comes out of the pharmaceutical company named Amicus Therapeutics. Based in Cranbury, New Jersey, with a second research facility in Southern California, the company is making gains in the pharmaceutical industry on the heel of announcements that the Food and Drug Administration (FDA) is planning to accept a New Drug Application (NDA) for the new drug Migalastat which was developed by Amicus Therapeutics.
An oral precision medicine, Migalasta will be the latest in an arsenal of treatments against Fabry disease. Industry followers of Amicus Therapeutics anxiously await its latest submission during the fourth quarter of 2017.
Reason For New Hope
Chief Medical Officer of Amicus …show more content…
alone battle Fabry Disease; moreover, Amicus Therapeutics believes that this sets a sound stage for further development of the new drug Migalastat.
In further statements, Jay Barth went on to say that data on Migalastat demonstrates that Amicus Therapeutics is data-driven and science-based and a formidable force to contend with in the pharmaceutical industry.
About Amicus Therapeutics
As a biotechnology company, Amicus Therapeutics is on the forefront of making its mark dealing globally with therapies for rare diseases. Through various initiatives, they have demonstrated a passion for developing medicines and technologies to help people with the rare diseases including: Fabry diseases, Epidermolysis Bullosa and connective skin disorders as well as Pompe disease.
As such, Migalastat is the first approved medicine for Fabry disease and the stellar drug from Amicus Therapeutics.
Their mission is using biotechnology to heal rare diseases, and it has an extensive trajectory of collaborating with the health care industry in general. This includes health care practitioners, individual patients, caregivers and organizations in the rare disease
An oral precision medicine, Migalasta will be the latest in an arsenal of treatments against Fabry disease. Industry followers of Amicus Therapeutics anxiously await its latest submission during the fourth quarter of 2017.
Reason For New Hope
Chief Medical Officer of Amicus …show more content…
alone battle Fabry Disease; moreover, Amicus Therapeutics believes that this sets a sound stage for further development of the new drug Migalastat.
In further statements, Jay Barth went on to say that data on Migalastat demonstrates that Amicus Therapeutics is data-driven and science-based and a formidable force to contend with in the pharmaceutical industry.
About Amicus Therapeutics
As a biotechnology company, Amicus Therapeutics is on the forefront of making its mark dealing globally with therapies for rare diseases. Through various initiatives, they have demonstrated a passion for developing medicines and technologies to help people with the rare diseases including: Fabry diseases, Epidermolysis Bullosa and connective skin disorders as well as Pompe disease.
As such, Migalastat is the first approved medicine for Fabry disease and the stellar drug from Amicus Therapeutics.
Their mission is using biotechnology to heal rare diseases, and it has an extensive trajectory of collaborating with the health care industry in general. This includes health care practitioners, individual patients, caregivers and organizations in the rare disease